Transient myeloproliferative disorder and eosinophilic pericardial effusion in a down syndrome neonate

Pediatric Hematology and Oncology

Volumn 25, Issue 2, 2008, Pages 123-129

  Shenoy, Rathika D ^a,b   Bhat, Kamalakshi G ^a   Kamath, Nutan ^a   Kumble, Yusuf ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b KMCH Attavar ^*  (India)

Author keywords

Down syndrome; Eosinophils; Pericardial effusion; Transient myeloproliferative disorder

Indexed keywords

PREDNISOLONE;

ANEMIA; ARTERIAL GAS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DOWN SYNDROME; EOSINOPHIL; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LABORATORY TEST; MALE; MYELOPROLIFERATIVE DISORDER; NEWBORN; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PHENOTYPE; PHYSICAL EXAMINATION;

ANTINEOPLASTIC AGENTS, HORMONAL; DOWN SYNDROME; EOSINOPHILS; HUMANS; INFANT, NEWBORN; MALE; MYELOPROLIFERATIVE DISORDERS; PERICARDIAL EFFUSION; PREDNISOLONE;

EID: 41149083029     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010801888220     Document Type: Article

References (19)

1. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
2. Concolino D, Pascuzzi A, Pietragalla E, Lia R, Canepa S, Strisciuglio P. High prevalence of isolated pericardial effusion in Down syndrome. Am J Med Genet A. 2005;132:331-332.
3. Dinleyici EC, Ucar B, Kilic Z, Dogruel N, Yarar C. Pericardial effusion due to hypothyroidism in Down syndrome: report of four cases. Neuro Endocrinol Lett. 2007;28(2).[Epub]
4. Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Sem Perinatol. 1997;21:97-101.
5. Kusanagi Y, Ochi H, Matsubara K, Ito M. Hypereosinophilic syndrome in a trisomy 21 fetus. Obstet Gynaecol. 1998;92:701-702.
6. Jones GR, Weaver M, Lang WE. Transient blastemia in phenotypically normal newborns. Am J Pediatr Hematol Oncol. 1987;9:153-157.
7. Wienberg AG, Schiller G, Windmiller J. Neonatal leukamoid reaction. Am J Dis Child. 1982;136:310.
8. Richards M, Welch J, Whatmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down syndrome. Arch Dis Child Fetal Neonatal Ed. 1998;79:F215-F217.
9. Abe K, Kajii T, Niikawa N. Disomic homozygosity in 21 trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. Hum Genet. 1989;82:313-316.
10. Lorber BJ, Freeman SB,Hassold T, et al. Characterization andmolecular analysis of nondisjunction in 18 cases of trisomy 21 and leukemia. Genes Chromosomes Cancer. 1992;4:222-227.
11. Huret JL, Leonard C. Chromosome 21 and platelets: a gene dosage effect? Clin Genet. 1997;51:140-141.
12. Suda J, Eguchi M, Akiyama Y, et al. Differentiation of blast cells from a Down's syndrome patient with transient myeloproliferative disorder. Blood. 1987;69:508-512.
13. Strobelt N, Ghidini A, Locatelli A, Vergani P, Mariani S, Biondi A. Intrauterine diagnosis and management of transient myeloproliferative disorder. Am J Perinatol. 1995;2:132-134.
14. Hirashima C, Eguchi Y, Kohmura Y, Minakami H, Sato I. Isolated pericardial effusion and transient abnormal myelopoiesis in a fetus with Down syndrome. J Obstet Gynaecol Res. 2000;26:303-306.
15. Karandikar NJ, Aquino DB, McKenna RW, Kroft SH. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: an immunophenotypic analysis. Am J Clin Pathol. 2001;116:204-210.
16. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down syndrome. Blood. 1988;72:15-23.
17. Miller JMcC, Sherrill MD, Hathaway WE. Thrombocythemia in the myeloproliferative disorder of Down's syndrome. Pediatrics. 1967;40:847-850.
18. Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid-specific genes in acute megakaryoblastic leukemia and transient myeloproliferative disorder in Down's syndrome. Br J Hematol. 1995;90:607-614.
19. Harigae H. GATA transcription factors and hematological diseases. Tohoku J Exp Med. 2006;210:1-9.